Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Dermatol Online J ; 24(5)2018 05 15.
Artículo en Inglés | MEDLINE | ID: mdl-30142736

RESUMEN

Severe bullous eruptions in systemic lupus erythematosus (SLE) patients include bullous SLE, Rowell syndrome, toxic epidermal necrolysis (TEN), and TEN-like eruption of acute cutaneous lupus (TEN-like ACLE). TEN-like ACLE, a rare manifestation of SLE that closely mimics TEN, can be distinguished by characteristic clinical and laboratory findings. A 27-year-old man with SLE who developed TEN-like ACLE after initiating mycophenolate mofetil for active SLE is reported. The reports of 37 women and six men  including our patient with TEN-like ACLE were also reviewed. The diagnosis of SLE or subacute cutaneous lupus erythematosus was either previously confirmed or established at the time of diagnosis of TEN-like ACLE in 41 patients. Fever was present in 59% of patients. The onset of TEN-like ACLE was either subacute (73%) or acute (27%). Thirteen cases did not clarify the nature of disease onset. The skin lesions often presented initially on sun-exposed sites (29 patients) and involved one or more mucous membranes (21 patients). A new medication may have caused the TEN-like ACLE in 67% of the patients. Systemic corticosteroids either alone or combined with hydroxychloroquine, intravenous immunoglobulin, or mycophenolate mofetil were the most commonly used treatment. Patients with TEN-like ACLE patients had an 89% survival.


Asunto(s)
Antiinflamatorios/efectos adversos , Lupus Eritematoso Cutáneo/tratamiento farmacológico , Ácido Micofenólico/efectos adversos , Síndrome de Stevens-Johnson/etiología , Adulto , Antiinflamatorios/uso terapéutico , Humanos , Masculino , Ácido Micofenólico/uso terapéutico
2.
Rheum Dis Clin North Am ; 43(3): 489-502, 2017 08.
Artículo en Inglés | MEDLINE | ID: mdl-28711148

RESUMEN

The evidence to date regarding corticosteroid exposure in pregnancy and select pregnancy and birth outcomes is limited and inconsistent. The authors provide a narrative review of published literature summarizing the findings for oral clefts, preterm birth, birth weight, preeclampsia, and gestational diabetes mellitus. Whenever possible, the results are limited to oral or systemic administration with a further focus on use in autoimmune disease. Although previous studies of corticosteroid exposure in pregnancy reported an increased risk of oral clefts in the offspring, more recent studies have not replicated these findings.


Asunto(s)
Enfermedades Autoinmunes/tratamiento farmacológico , Glucocorticoides/administración & dosificación , Glucocorticoides/efectos adversos , Anomalías de la Boca/inducido químicamente , Complicaciones del Embarazo/tratamiento farmacológico , Femenino , Glucocorticoides/farmacología , Humanos , Placenta/efectos de los fármacos , Embarazo , Resultado del Embarazo , Factores de Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA